{"name":"Optimer Pharmaceuticals","permalink":"optimer-pharmaceuticals","crunchbase_url":"http://www.crunchbase.com/company/optimer-pharmaceuticals","homepage_url":"http://www.optimerpharma.com/","blog_url":"","blog_feed_url":"","twitter_username":"","category_code":"biotech","number_of_employees":null,"founded_year":null,"founded_month":null,"founded_day":null,"deadpooled_year":null,"deadpooled_month":null,"deadpooled_day":null,"deadpooled_url":null,"tag_list":"","alias_list":"","email_address":"","phone_number":"858.909.0736","description":"","created_at":"Tue Feb 08 04:46:00 UTC 2011","updated_at":"Tue Feb 08 04:47:44 UTC 2011","overview":"<p>Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. It has two late-stage anti-infective product candidates, fidaxomicin and Pruvel (prulifloxacin). Optimerâ€™s development efforts are focused on products that treat gastrointestinal infections, and related diseases where therapies have limitations. Its product portfolio includes Fidaxomicin, Pruvel, CEM-101, OPT-822/OPT-821 Combination Therapy and OPT-88. </p>","image":{"available_sizes":[[[150,61],"assets/images/resized/0012/0933/120933v1-max-150x150.png"],[[250,101],"assets/images/resized/0012/0933/120933v1-max-250x250.png"],[[263,107],"assets/images/resized/0012/0933/120933v1-max-450x450.png"]],"attribution":null},"products":[],"relationships":[{"is_past":false,"title":"President & CEO","person":{"first_name":"Pedro","last_name":"Lichtinger","permalink":"pedro-lichtinger","image":null}}],"competitions":[],"providerships":[],"total_money_raised":"$0","funding_rounds":[],"investments":[],"acquisition":null,"acquisitions":[],"offices":[{"description":"","address1":"10110 Sorrento Valley Rd.","address2":"Suite C","zip_code":"92121","city":"San Diego","state_code":"CA","country_code":"USA","latitude":null,"longitude":null}],"milestones":[{"description":"Optimer lands $224M licensing pact for promising antibiotic","stoned_year":2011,"stoned_month":2,"stoned_day":7,"source_url":"http://www.fiercebiotech.com/story/optimer-lands-224m-licensing-pact-promising-antibiotic/2011-02-07?utm_medium=rss&utm_source=rss","source_text":"","source_description":"Optimer lands $224M licensing pact for promising antibiotic","stoneable_type":"Company","stoned_value":null,"stoned_value_type":null,"stoned_acquirer":null,"stoneable":{"name":"Optimer Pharmaceuticals","permalink":"optimer-pharmaceuticals"}}],"ipo":{"valuation_amount":null,"valuation_currency_code":"USD","pub_year":null,"pub_month":null,"pub_day":null,"stock_symbol":"NASDAQ:OPTR"},"video_embeds":[],"screenshots":[],"external_links":[]}